BioCentury
ARTICLE | Clinical News

Celldex reports Phase I/II data for varlilumab plus Opdivo in solid tumors

June 1, 2018 6:23 PM UTC

Celldex Therapeutics Inc. (NASDAQ:CLDX) reported data from 90 patients with advanced refractory solid tumors in a Phase I/II trial showing that varlilumab (CDX-1127) plus PD-1 inhibitor Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) was well tolerated. In 49 evaluable patients with ovarian cancer, varlilumab plus Opdivo led to five partial responses and 19 cases of stable disease. In 41 evaluable patients with colorectal cancer, the combination led to two partial responses and seven cases of stable disease. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Celldex and BMS are partnered to conduct the open-label, dose-escalation, U.S. trial (see BioCentury, May 19, 2014)...